Tom van Hagen
Clinical Oncology Society of Australia Annual Scientific Meeting 2018
Days
Monday, 12th November
Tuesday, 13th November
Wednesday, 14th November
Thursday, 15th November
Search
Speakers
Tom van Hagen
Abstracts this author is presenting:
Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic Merkel cell carcinoma (mMCC) progressed on chemotherapy
—
Poster Session 2
Avelumab treatment of Australian patients with metastatic Merkel cell carcinoma (mMCC): experience from an expanded access program (EAP)
—
Breakfast Session: Best of the Best Poster discussion A - Translational and Clinical Research